Parathyroid hormone is not involved in prostate growth in patients with benign prostatic hyperplasia

Prostate

Volumn 71, Issue 11, 2011, Pages 1210-1215

  Kim, Won Tae ^a,b   Choi, Young Deuk ^b   Park, Cheol ^a   Kim, Young Won ^a   Yun, Seok Joong ^a   Kim, Isaac Yi ^c   Kim, Wun Jae ^a  

^a Chungbuk National University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

parathyroid hormone; prostate; prostatic hyperplasia

Indexed keywords

CALCIUM; CREATININE; PARATHYROID HORMONE; PROSTATE SPECIFIC ANTIGEN; VITAMIN D;

AGE; AGED; ARTICLE; BODY MASS; CALCIUM BLOOD LEVEL; CREATININE BLOOD LEVEL; HISTOPATHOLOGY; HORMONE BLOOD LEVEL; HUMAN; HUMAN TISSUE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE HYPERTROPHY; SOUTH KOREA; TRANSURETHRAL INCISION OF THE PROSTATE; VITAMIN BLOOD LEVEL;

AGED; CALCIUM; HUMANS; MALE; MIDDLE AGED; PARATHYROID HORMONE; PROSTATE; PROSTATIC HYPERPLASIA; TUMOR MARKERS, BIOLOGICAL; VITAMIN D;

EID: 79958214889     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21336     Document Type: Article

References (21)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL,. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132 (3): 474-479. (Pubitemid 14026148)
2. Lee C, Kozlowski JM, Grayhack JT,. Etiology of benign prostatic hyperplasia. Urol Clin North Am 1995; 22 (2): 237-246.
3. Roehrborn CG, Mcconnell JD,. Benign prostatic hyperplasia: Etiology, pathophysiology, epidemiology, and natural hiostory. In:, Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh's Urology. Pennsylvania: Saunders; 2007. pp 2727-2746.
4. Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE, Upadhya P,. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3. Cancer Res 1992; 52 (3): 515-520.
5. Konety BR, Schwartz GG, Acierno JS, Becich MJ, Getzenberg RH,. The role of vitamin D in normal prostate growth and differentiation. Cell Growth Differ 1996; 7 (11): 1563-1570. (Pubitemid 26378351)
6. Skinner HG, Schwartz G,. The relation of serum parathyroid hormone and serum calcium to serum levels of prostate-specific antigen: A population-based study. Cancer Epidemiol Biomarkers Prev 2009; 18 (11): 2869-2873.
7. Wu AH, Whittemore AS, Kolonel LN, John EM, Gallagher RP, West DW, Hankin J, Teh CZ, Dreon DM, Paffenbarger RS Jr., Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol Biomarkers Prev 1995; 4 (7): 735-741.
8. Matthews GJ, Motta J, Fracehia JA,. The accuracy of transrectal ultrasound prostate volume estimation: Clinical correlations. J Clin Ultrasound 1996; 24 (9): 501-505. (Pubitemid 26347786)
9. Peehl DM, Krishnan AV, Feldman D,. Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer. J Nutr 2003; 133 (7 Suppl): 2461S-2469S. (Pubitemid 36828855)
10. Krishnan AV, Peehl DM, Feldman D,. Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. J Cell Biochem 2003; 88 (2): 363-371. (Pubitemid 36119910)
11. Schneider A, Kalikin LM, Mattos AC, Keller ET, Allen MJ, Pienta KJ, McCauley LK,. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 2005; 146 (4): 1727-1736. (Pubitemid 40396881)
12. Schwartz G, Hall MC, Stindt D, Patton S, Lovato J, Torti FM,. Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. Clin Cancer Res 2005; 11 (24): 8680-8685. (Pubitemid 43005917)
13. Ritchie CK, Thomas KG, Andrews LR, Tindall DJ, Fitzpatrick LA,. Effects of the calciotrophic peptides calcitonin and parathyroid hormone on prostate cancer growth and chemotaxis. Prostate 1997; 30 (3): 183-187. (Pubitemid 27149277)
14. Gupta A, Aragaki C, Gotoh M, Masumori N, Ohshima S, Tsukamoto T, Roehrborn CG,. Relationship between prostate specific antigen and indexes of prostate volume in Japanese men. J Urol 2005; 173 (2): 503-506.
15. Chang Y, Lin AT, Chen K, Wu HH, Kuo J, Huang WJ, Lu SH, Hsu YS, Chung HJ, Chang SC,. Correlation between serum prostate specific antigen and prostate volume in Taiwanese men with biopsy proven benign prostatic hyperplasia. J Urol 2006; 176 (1): 196-199. (Pubitemid 43833176)
16. Lee SE, Chung JS, Han BK, Moon KH, Hwang SI, Lee HJ, Choe G, Hong SK,. Relationship of prostate-specific antigen and prostate volume in Korean men with biopsy-proven benign prostatic hyperplasia. Urology 2008; 71 (3): 395-398. (Pubitemid 351374707)
17. Soygr T, Kpeli B, Aydos K, Kpeli S, Arikan N, Müftüoǧlu YZ,. Effect of obesity on prostatic hyperplasia: Its relation to sex steroid levels. Int Urol Nephrol 1996; 28 (1): 55-59. (Pubitemid 26172023)
18. Daniell HW,. Larger prostatic adenomas in obese men with no associated increase in obstructive uropathy. J Urol 1993; 149 (2): 315-317. (Pubitemid 23097582)
19. Banez L, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, Wang Y, Terris MK, Aronson WJ, Presti JC Jr, Kane CJ, Amling CL, Moul JW, Freedland SJ,. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 2007; 298 (19): 2275-2280. (Pubitemid 350146217)
20. Grubb RL, Black A, Izmirlian G, Hickey TP, Pinsky PF, Mabie JE, Riley TL, Ragard LR, Prorok PC, Berg CD, Crawford ED, Church TR, Andriole GL Jr, PLCO Project Team. Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev 2009; 18 (3): 748-751.
21. Werny DM, Thompson T, Saraiya M, Freedman D, Kottiri BJ, German R, Wener M,. Obesity is negatively associated with prostate-specific antigen in U.S. men, 2001-2004. Cancer Epidemiol Biomarkers Prev 2007; 16 (1): 70-76. (Pubitemid 46174266)